NCT06179511 - Study of AZD9829 in CD123+ Hematological Malignancies | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 7, 2027

Study Completion Date

January 7, 2027

Conditions

Hematological Malignancies

Interventions

DRUG

AZD9829

AZD9829 will be administered by IV infusion

DRUG

AZD9829

AZD9829 will be administered by IV infusion

Trial Locations (24)

3084

RECRUITING

Research Site, Heidelberg

10002

RECRUITING

Research Site, Taipei

10021

SUSPENDED

Research Site, New York

27514

RECRUITING

Research Site, Chapel Hill

37007

RECRUITING

Research Site, Salamanca

40138

RECRUITING

Research Site, Bologna

43210

RECRUITING

Research Site, Columbus

53226

RECRUITING

Research Site, Milwaukee

60590

RECRUITING

Research Site, Frankfurt

63110

RECRUITING

Research Site, St Louis

77030

RECRUITING

Research Site, Houston

91010

RECRUITING

Research Site, Duarte

300020

RECRUITING

Research Site, Tianjin

450008

NOT_YET_RECRUITING

Research Site, Zhengzhou

510515

RECRUITING

Research Site, Guangzhou

VIC 3000

RECRUITING

Research Site, Melbourne

227-8577

RECRUITING

Research Site, Kashiwa

545-8586

RECRUITING

Research Site, Osaka

910-1193

RECRUITING

Research Site, Yoshida-gun

03080

RECRUITING

Research Site, Seoul

05505

RECRUITING

Research Site, Seoul

08035

RECRUITING

Research Site, Barcelona

Unknown

RECRUITING

Research Site, Tainan City

M204BX

RECRUITING

Research Site, Manchester